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Objective: Cough is a typical side effect of angiotensin-converting enzyme (ACE) inhibitors, 
though its frequency quantitatively varies among the different compounds. Data on the incidence 
of cough with the lipophilic third-generation ACE inhibitor zofenopril are scanty and never 
systematically analyzed. The purpose of this paper is to give an overview on the epidemiology, 
pathophysiology, and treatment of ACE inhibitor-induced cough and to assess the incidence of 
cough induced by zofenopril treatment.
Methods: Published and unpublished data from randomized and postmarketing zofenopril 
trials were merged together and analyzed.
Results: Twenty-three studies including 5794 hypertensive patients and three studies including 
1455 postmyocardial infarction patients exposed for a median follow-up time of 3 months to 
zofenopril at doses of 7.5–60 mg once-daily were analyzed. The incidence of zofenopril-induced 
cough was 2.6% (range 0%–4.2%): 2.4% in the hypertension trials (2.4% in the double-blind 
randomized studies and 2.4% in the open-label postmarketing studies) and 3.6% in the double-
blind randomized postmyocardial infarction trials. Zofenopril-induced cough was generally of 
a mild to moderate intensity, occurred significantly (P , 0.001) more frequently in the first 
3–6 months of treatment (3.0% vs 0.2% 9–12 months), and always resolved or improved upon 
therapy discontinuation. Zofenopril doses of 30 mg and 60 mg resulted in significantly (P = 0.042) 
greater rate of cough (2.1% and 2.6%, respectively) than doses of 7.5 mg and 15 mg (0.4% and 
0.7%, respectively). In direct comparison trials (enalapril and lisinopril), incidence of cough was 
not significantly different between zofenopril and other ACE inhibitors (2.4% vs 2.7%).
Conclusion: Evidence from a limited number of studies indicates a relatively low incidence of 
zofenopril-induced cough. Large head-to-head comparison studies versus different ACE inhibi-
tors are needed to highlight possible differences between zofenopril and other ACE inhibitors 
in the incidence of cough.
Keywords: cough, ACE inhibitor, zofenopril, arterial hypertension, myocardial infarction, 
heart failure
Introduction
Zofenopril calcium, a prodrug of the active compound zofenoprilat, is a highly lipo-
philic third-generation angiotensin-converting enzyme (ACE) inhibitor, character-
ized by a high degree of tissue penetration and long-term cardiac ACE inhibition.1–4 
Zofenopril, alone or in combination with a diuretic, has been successfully and safely 
employed in the treatment of acute myocardial infarction,5–7 heart failure,8,9 and essen-
tial hypertension.1–3,10–17
Lipophilicity confers zofenopril a high potency (five to six times more potent than 
captopril and twice as potent as enalaprilat and fosinoprilat, but three times less potent Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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than ramiprilat),18,19 significant tissue selectivity (inhibition 
of cardiac ACE is 90% 1 hour after administration, 60% 
after 8 hours, and 45% after 24 hours),20 rapid onset (in 
hypertensive patients maximal blood pressure reductions are 
observed 2 hours after receiving zofenopril), and long dura-
tion of action (approximately 70% of the peak blood pressure 
response is maintained after 24 hours).10,11 The lipophilicity 
of zofenopril might potentially be associated with a low risk 
of coughing, but a systematic evaluation of this adverse event 
in patients treated with this drug has never been done.
The objective of the present paper was thus to specifically 
assess the incidence and characteristics of cough induced 
by zofenopril treatment by analyzing individual data of 
published and unpublished double-blind randomized and 
open-label postmarketing studies based on this drug. The 
results of this systematic review will be preceded by an ample 
overview and update on the epidemiology, pathophysiology, 
and treatment of ACE inhibitor-induced cough based on a 
thorough search of publications in the most popular electronic 
databases (PubMed, Embase, Cochrane library).
ACE inhibition and cough
General feature of ACe inhibitor-induced 
cough
ACE inhibitors are, together with beta-blockers and inhaled 
agents, the most common cause of reported cases of iat-
rogenic cough, with a rate of 75%.21 First cases of cough 
associated with ACE inhibitors were reported in the early 
1980s with captopril.22,23 Since then cough has been reported 
as a typical side effect with all ACE inhibitors and it is likely 
to be a class side effect of these drugs; cough is not dose 
related and it is already observed with the lowest dose of 
the various active principles.24–27 Though it is considered a 
typical class side effect of ACE inhibitors, it is well known 
that incidence of cough may quantitatively vary among the 
different ACE inhibitors.28
ACE inhibitor-associated cough may take weeks or even 
months to develop, and it is reversible upon discontinuation 
of the drug. In first reports, time of onset of cough after 
starting an ACE inhibitor usually ranged from 3 days to 
12 months.29 Although cough usually resolves within 1 day 
to 4 weeks of the cessation of therapy with the offending 
drug, in subgroups of individuals cough has been shown to 
linger for up to 3 months.24,25,29,30 After stopping treatment, 
recovery from cough is usually rapid and complete and there 
is no indication of long-term effects.24
The cough is typically dry, nonproductive, tickling, 
paroxysmal, often bothersome, associated with scratching 
sensation in the throat, and it is frequently worse when lying 
down.31,32 It is an annoying although harmless side effect,33 
but it is persistent.34 Sometimes cough may be severe enough 
to cause some deterioration in well-being: cough may disturb 
sleep and wake up patients, usually early in the morning, it 
may cause vomiting, voice changes, and urinary inconti-
nence, or may be debilitating.24,35,36 Cough may also lead to 
medication change and unnecessary diagnostic evaluation, 
and it may be associated with some depression and a tendency 
for increased fatigue: in one study this adverse drug reaction 
was associated with increased worry or discomfort in 49% 
of patients and with lower patient satisfaction.37
Cough is in the majority of cases benign, and only lim-
ited cases of lung damage, such as interstitial infiltrates, 
have been associated to treatment with an ACE inhibitor.38 
Asthmatic patients do not seem to be at increased risk for 
ACE inhibitor-induced cough (14%–16% incidence of 
cough reported in patients with asthma treated with an ACE 
inhibitor versus 13% of patients without a prior history of 
bronchospasm).25,39,40
ACE inhibitor-induced cough may be often misdiagnosed, 
though awareness of this side effect has increased among 
physicians due to the widespread use of ACE inhibitors and 
the consequent increased chance of occurrence of such side 
effect.31
If the clinician fails to recognize the relationship between 
ACE inhibitor treatment and cough, the patient may be sub-
jected to extensive and unnecessary evaluations, diagnostic 
tests, and consultations. One simple diagnostic procedure 
may be to stop treatment and to check whether cough recurs 
after treatment withdrawal and rechallenge: indeed, one ran-
domized controlled trial demonstrated that 30% of patients 
did not develop a cough on third trial.30 Treatment withdrawal 
in this case must be done with caution, particularly in patients 
with moderate to severe hypertension or under multiple drug 
treatment, since abrupt discontinuation of successful antihy-
pertensive therapy can result in a return of blood pressure to 
pretreatment levels. However, this blood pressure increase 
is usually gradual with ACE inhibitors, particularly in mild 
hypertensive subjects, and it rarely causes a withdrawal 
syndrome.
epidemiology
Cough is thought to be a class effect, but there is consider-
able variation in estimates of the occurrence of coughing 
due to ACE inhibitors in the various systematic reviews 
and meta-analyses, probably due to the method used for 
its investigation.24,25,34,41–55 These differences reflect study Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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design (postmarketing or general population studies versus 
randomized controlled studies), method of ascertaining the 
presence of cough (spontaneous reports, systematic inquiry, 
patient self-reporting), method of measuring occurrence of 
the phenomenon, and the size of the study.25,56,57 The complex 
pathophysiology of the phenomenon may also explain why 
this adverse effect is variable in occurrence (3%–35% in the 
various studies).31
Postmarketing surveillance and general population studies 
report a lower (0%–3%) incidence of ACE inhibitor-induced 
cough as compared to randomized controlled studies.25,42,58–63 
The higher observed rates of cough found in randomized 
controlled trials (13% to 25%–35%) are probably due to the 
fact that in such studies patients were queried systematically 
for the symptom.
Risk of coughing has been found in some cases to be lower 
with newer ACE inhibitors probably because of an increased 
awareness of this symptom with time rather than for real dif-
ferences in pharmacological effects. A conservative estimate 
of the incidence of ACE inhibitor-induced cough might be 
5%–10% of treated patients.35
Cough due to ACE inhibitor treatment is common not 
only in hypertensive-treated patients but also in heart failure-
treated patients. In 670 patients hospitalized for symptomatic 
chronic heart failure, of which 74% were receiving an ACE 
inhibitor alone or in combination with other drugs, cough due 
to an ACE inhibitor was reported in approximately 2% of sub-
jects.46 In a meta-analysis of 9668 patients with chronic heart 
failure or left ventricular dysfunction, about 2% of patients 
were withdrawn from the study because of cough, which 
represented 5% of all causes of treatment withdrawal.64
Patients treated with ACE inhibitors for chronic heart 
failure seem to cough more frequently than those treated for 
hypertension. In a prospective study involving 268 patients, 
cough was developed during the 1 year of follow-up by 14% 
of patients with hypertension and by 26% of patients with 
chronic heart failure, probably because of a lower threshold 
for cough in the latter group.57
Cough due to ACE inhibitors occurs more frequently in 
women (relative risk [RR]: 2–2.5 compared to men),24,65–67 
elderly (RR: 1.5–2.0 compared to younger people),53 non-
smokers (RR: 3.0 compared to smokers),25,66 and patients 
of Chinese or Asiatic origin (RR: 2.7 compared to white 
people).68,69 A study developed and validated a predicting 
model for risk of development of ACE inhibitor-induced 
cough within 6 months from starting treatment by using 
information available at first prescription for 567 patients.70 
In the total cohort of subjects, 13% developed ACE 
  inhibitor-induced cough. Independent predictors of cough 
were older age (adjusted odds ratio [OR]: 2.1 for age 
60–69 years), female gender (OR: 2.3), East Asian origin 
(OR: 4.3), no history of previous ACE inhibitor use (OR: 2.4), 
and history of cough due to another ACE inhibitor (OR: 29). 
This model could help in avoiding the prescription of ACE 
inhibitors in patients at higher risk of developing cough.
Pathophysiology
A possible pathophysiological mechanism for ACE inhibitor-
associated cough is depicted in Figure 1. The pathogenesis 
of the phenomenon is not completely known, but cough is 
thought to be related to a cascade of effects that begins with 
the accumulation of kinins and then involves arachidonic 
acid metabolism and nitric oxide generation.71 ACE is syn-
onymous with kininase II and bradykinin dehydrogenase, 
the enzyme responsible for bradykinin breakdown. ACE 
inhibition thus blocks this pathway and leads to accumula-
tion of bradykinin in the airways, a substance recognized 
as a bronchoconstrictor. Bradykinin has many local effects, 
including the release of histamine, and also interferes with 
locally-produced neurotransmitters such as substance P and 
neuropeptide Y.25 Both bradykinin and substance P may inter-
fere with type I receptors at peripheral nerve endings, perhaps 
mediated by unmyelinated or vagal afferent C-fiber, which 
have irritant effects on the bronchial mucosa.72 The increased 
cough response to the specific C fiber stimulant capsaicin, a 
local irritant on mucosal membranes, both in patients who 
cough and in normal volunteers, is a demonstration that in 
presence of an ACE inhibitor the cough reflex is increased. 
This sensitization of the cough reflex may potentiate other 
causes of chronic cough.73
Other possible mechanisms for bronchoconstriction are 
direct action on smooth muscle and/or indirect inflammatory 
Bradykinin Substance P
ACE
inhibition
↑ Prostaglandins
(PGE2-PG12)
↑ Histamine
↑ Leukotrienes
Inactive peptides
Type J receptors at peripheral vagal afferents
ending / non-myelinated or C-fibers
Cough
Figure 1 Pathophysiology of angiotensin-converting enzyme inhibitor-induced cough.71,72
Abbreviations: ACe, angiotensin-converting enzyme; PG, prostaglandin.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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activity, like local edema.74 Bradykinin may also activate 
local release of histamine from mast cells, which might be a 
mediator of the ACE inhibitor-induced cough and be part of 
the tussive effect.33,62 The indirect demonstration that ACE 
inhibitor-induced cough is linked to accumulation of kinins, 
is proved by the fact that ACE is able to degrade kinins and 
that ACE inhibitor protussive effect is reduced by kinin 
antagonists.74
Local effects on prostaglandin synthesis have also been 
suggested, since prostaglandins act locally as inflammatory 
agents. Besides directly interacting with C fibers, bradykinin 
may also cause bronchoconstriction indirectly by release of 
arachidonic acid derivatives such as leukotrienes and pros-
taglandin E2 and I2.25,75,76 Prostaglandin E2 stimulates the 
unmyelinated afferent sensory C fibers (as does bradykinin 
through type J receptors), resulting in cough. Treatment with 
a prostaglandin synthetase inhibitor (eg, indomethacin) may 
alleviate the cough in affected patients.
Bradykinin has been shown to induce the production of 
nitric oxide, and there is some evidence that this product, 
which is subject to regulation by other pathways, may pro-
mote cough through pro-inflammatory mechanisms.71
Thus, there are suggested pharmacological reasons for 
the cough, but it is not clear why relatively few patients 
experience this side effect. It is thought that the mechanism 
responsible for ACE inhibitor-related cough might be an 
increased sensitivity of the cough reflex, probably a genetic 
polymorphism.77 Some evidence has suggested that the thera-
peutic effect of ACE inhibitors may involve the activation 
of bradykinin receptors and that bradykinin receptor gene 
polymorphism is associated with the cough that is related 
to ACE inhibitors.78,79 Subjects with ACE inhibitor-induced 
cough demonstrate increased cough reflex sensitivity to 
experimental stimulation with capsaicin, which resolves after 
the discontinuation of therapy with the inciting drug.73,77,80
More recently, hypothesis of genetic predisposition to 
ACE inhibitor cough has been supported by a study in which 
patients with a history of developing this side effect showed 
a lower activity of an enzyme called aminopeptidase P. This 
enzyme has an important role in degrading bradykinin and 
its reduced activity may be partially explained by genetic 
variation.81
Treatment
Numerous small studies have evaluated various drugs, such 
as cromolyn, baclofen, theophylline, sulindac, and local 
anesthetics use82–86 as potential therapies for ACE inhibitor-
induced cough, but none of them seem to be resolutive. 
Also, antitussive drugs, such as antihistamines, are relatively 
ineffective in patients with cough following treatment with 
ACE inhibitors, although useful in cases of chronic cough 
due to other cause or idiopathic chronic cough.33 This is prob-
ably related to the specific mechanism responsible for ACE 
inhibitor-related cough, which is only marginally affected by 
treatment with antitussive drugs, acting on the symptoms, but 
not on the specific cause of cough.86
The only appropriate intervention for ACE inhibitor-
induced cough is the cessation of therapy with the offending 
agent. Commonly, in half of the patients developing cough 
following treatment with ACE inhibitor, the drug has to 
be discontinued.32 Only very rarely may a dose reduction 
lead to improvement and indeed this confirms evidence that 
incidence of cough does not substantially vary with dose.33,87 
Cough is usually remitting within a few days (1–4 days) 
after the agent is discontinued, but can rarely take as long 
as 4–12 weeks to subside.25,34
According to European and American guidelines,88,89 in 
patients with persistent or intolerable ACE inhibitor-induced 
cough, therapy should be switched to an angiotensin II 
antagonist with which the incidence of associated cough 
appears to be similar to that for the control drug, or to an 
appropriate agent of another drug class.31 Indeed, consistent 
fair-to-good quality evidence has shown that ACE inhibitors 
are associated with a risk of cough as much as three times 
higher than that of angiotensin II antagonists.42,90
As indicated by current guidelines,88,89 for patients whose 
cough resolves after the cessation of ACE inhibition therapy 
and for whom there is a compelling reason for treatment with 
these agents, a repeat trial of ACE inhibitor therapy may be 
attempted. One randomized double-blind, parallel-group 
controlled trial demonstrated that about 30% of patients with 
ACE inhibitor-induced cough who had been challenged and 
dechallenged twice did not develop cough after a third trial 
of ACE inhibitor therapy.91
Association of an angiotensin II antagonist to an ACE 
inhibitor is not a useful option for reducing the risk of 
cough. In the ONgoing Telmisartan Alone and in combina-
tion with Ramipril Global Endpoint Trial study, the rate 
of discontinuation of study medication due to cough was 
similar in the 8576 patients treated with ramipril (4.2%) and 
in the 8502 patients treated with combination of ramipril 
and telmisartan (4.6%).92 In a meta-analysis of nine trials, 
involving 18,160 patients with heart failure or left ventricular 
dysfunction, risk of cough in the 9199 patients receiving 
combination therapy was not significantly different from that 
of patients receiving an ACE inhibitor alone (RR: 0.84; 95% Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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confidence interval 0.65–1.09).93 Also, the combination of 
low-dose ACE inhibitors with other antihypertensive drugs 
does not substantially reduce the risk of cough.87
Zofenopril and cough
Methodology of the review
Individual published and unpublished data from double-blind 
randomized and open-label postmarketing therapeutic trials 
based on zofenopril treatment were retrieved from the manu-
facturer and merged together in an electronic database.1–7,10–17 
In all studies, the prevalence of cough was monitored and 
assessed at each visit by the physician objectively, by physi-
cal examination, or subjectively by asking the patient a non-
leading question or by patient’s spontaneous reporting. No 
specific questionnaire was used to assess the features of ACE 
inhibitor-induced cough. The physician assigned a severity 
category to cough, according to the following scale: (a) 
mild (an easily tolerated cough, causing minimal discomfort 
and not interfering with everyday activities), (b) moderate 
(a sufficiently discomforting cough, interfering with normal 
everyday activities), and (c) severe (cough preventing normal 
everyday activities). Data analysis was carried out by SPSS 
Statistical Package (v 11.5; IBM Corporation, Armonk, NY). 
Analysis of variance was used for comparison of continuous 
variables and a chi-square test for comparison of proportions. 
Data are summarized as mean values (±standard deviation) 
or as absolute and relative (%) frequencies.
General characteristics of the studies, with reference to 
published and unpublished data, study design, study drug 
doses, and inclusion criteria, are reported in Table 1. The 
database included 5794 treated hypertensive patients and 
1455 treated postmyocardial infarction patients. A total of 
7249 subjects had been exposed to zofenopril in dosages 
7.5–60 mg once-daily from as early as 1 month to 1 year 
(median follow-up time 3 months). According to analysis 
of zofenopril studies, the overall incidence of cough was of 
190 patients out of 7429 (2.6%, range 0%–4.2%). In the follow-
ing paragraphs, a detailed report on the incidence of cough for 
hypertension and postmyocardial infarction studies by study 
design, treatment duration, and dosages will be shown.
Results
Cough under zofenopril in hypertension trials
In the zofenopril hypertension studies, drug-related cough 
was experienced by 137 (2.4%) of the 5794 patients receiving 
zofenopril regimen: there was no significant difference in the 
incidence of cough between double-blind randomized   studies 
(93 patients, 2.4%) and open-label studies (44 patients, 
2.4%; P = 0.987), or the published and unpublished studies 
(2.8% vs 2.2%, P = 0.153) (Figure 2A).1,10–17 Expectedly, 
in placebo controlled studies, cough was reported signifi-
cantly (P = 0.035) more often with zofenopril (4.1%) than 
with placebo (1.6%). Elderly patients ($65 years) did not 
experience cough more frequently than nonelderly (4.4% vs 
3.8%; P = 0.496), and cough did not occur in patients under 
40 years of age (Figure 2A). Significantly more women 
than men experienced cough (3.8% vs 1.3%, P = 0.042) 
(Figure 2A).
Cough was generally mild to moderate and tended 
to occur significantly more often (P , 0.001) in the first 
6 months of treatment. There was no evidence of an increased 
incidence of cough during long-term trials, once the relative 
length of observation was taken into account. As reported in 
Figure 3, incidence of cough was 1.9% in trials lasting up 
to 3 months, 3.0% in trials lasting more than 3 months and 
up to 6 months, 1.5% in trials lasting more than 6 months 
and up to 9 months, and only 0.2% in long-term trials with 
duration up to 12 months. The occurrence of cough showed 
dose dependency, with doses of 30 mg and 60 mg result-
ing in significantly (P = 0.042) greater frequency of events 
(2.1% and 2.6% of treated patients, respectively) than doses 
of 7.5 mg (0.4%) and 15 mg (0.7%) (Figure 4). Neither 
respiratory tract disease antedating zofenopril therapy nor 
concomitant use of other medications appears to predispose 
patients to zofenopril-associated cough. Of the 2535 patients 
for which information on pretreatment with ACE inhibitor 
was available, 2.5% developed cough during treatment with 
zofenopril.
Among the patients with zofenopril-associated cough, 
23.8% discontinued treatment due to this side effect, 38.1% 
reported resolution of the cough without interruption of 
zofenopril, 26.2% had a persistent cough to the end of the 
study without discontinuing zofenopril. Cough resolved or 
improved upon discontinuation from therapy for all patients 
in whom the outcome was reported, and in the majority of 
patients it either disappeared during treatment continuation 
or was mild enough to allow the continuation of zofenopril 
treatment until the planned study conclusion.
Trials directly comparing safety of zofenopril with that of 
other ACE inhibitors reported a slightly, but not significantly 
(P = 0.846), lower occurrence of cough under zofenopril as 
compared to enalapril or lisinopril (2.4% vs 2.7%) (  Figure 2B). 
The same was observed with beta-blockers, such as atenolol 
or propranolol (2.0% vs 2.8%, P = 0.688) (Figure 2B). The 
rate of cough during zofenopril was   significantly (P = 0.009) 
higher than that observed during treatment with angiotensin II Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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antagonist losartan (7/165 treated patients, 4.7% vs none 
under losartan) and not significantly (P = 0.145) greater than 
under candesartan (2/114 treated patients, 1.8% vs none under 
candesartan) (Figure 2B).
Combination with hydrochlorothiazide does not seem to 
significantly increase the chance of coughing in zofenopril-
treated patients. In three double-blind randomized studies, 
including 1008 patients with mild to moderate   essential hyper-
tension who received zofenopril 15–60 mg (410 patients) or 
zofenopril 15–60 mg plus hydrochlorothiazide 12.5–25 mg 
(598 patients), the overall incidence of cough was 2.8%: 
2.4% in the zofenopril monotherapy group (82.9% of patients 
receiving the usual dose of 30 mg) and 3.0% in the zofeno-
pril plus hydrochlorothiazide group (76.8% of patients were 
receiving the usual proposed dose of zofenopril 30 mg plus 
hydrochlorothiazide 12.5 mg) (P = 0.588) (Figure 2B).1,3
Cough under zofenopril in postmyocardial  
infarction studies
As mentioned above, zofenopril has also been largely 
employed in double-blind randomized trials in patients with 
myocardial infarction. The overall rate of cough in these trials 
was 3.6% (53/1455 treated patients) (Figure 5).
In the Survival of Myocardial Infarction Long-term 
Evaluation study group-1 (SMILE-1) study,5 1556 patients 
were enrolled within 24 hours after the onset of symptoms 
of acute myocardial infarction and randomly assigned to 
double-blind treatment with either placebo or zofenopril for 
6 weeks. The initial dose of zofenopril was 7.5 mg and it 
could be progressively doubled up to 60 mg. At the end of the 
study the target daily dose of 60 mg was achieved in 78.8% 
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of subjects. In the 772 patients treated with zofenopril, the 
major adverse side effect and main reason for discontinua-
tion of treatment was hypotension: drug-related cough was 
reported by 30 patients (3.9%) and did not lead to study 
withdrawal in any patient. The rate of cough was slightly, 
but not significantly (P = 0.088), higher in the control group 
(5.7%) treated with placebo.
The SMILE-1 study was followed by the SMILE-2 study,6 
which blindly assessed the efficacy of zofenopril at doses 
ranging from 7.5–60 mg daily against lisinopril 2.5–10 mg 
daily in 1204 thrombolyzed patients with acute myocardial 
infarction, in whom treatment was started within 48 hours 
from the onset of symptoms. During the 6 weeks of study 
treatment, drug-related cough was reported by 21 of the 
504 patients treated with zofenopril (4.2%) and by 17 of the 
520 patients treated with lisinopril (3.3%), with no statisti-
cally significant difference between the two treatment groups 
(P = 0.448).
In the SMILE-1 and SMILE-2 studies, the short follow-up 
period did not allow assessment of tolerability on long-term 
treatment. This was possible in the SMILE-3 (SMILE-
ischemia) study,7 which enrolled 349 postmyocardial patients 
with preserved left ventricular ejection fraction treated 
for 6 months with zofenopril 30–60 mg or placebo. In the 
179 patients treated with zofenopril, drug-related cough in 
response to treatment occurred in two patients (1.1%), which 
showed no significant difference (P = 0.579) to the rate 
observed in the placebo group (one patient, 0.6%).
Discussion
The aim of this paper was to produce evidence on drug-
related cough under zofenopril in clinical trials. This infor-
mation is scanty because some data were never published 
or systematically analyzed before. An analysis of original 
double-blind randomized or open-label postmarketing studies 
based on zofenopril treatment confirmed that the use of such 
an ACE inhibitor may be associated with the occurrence of 
this side effect.
Though it was beyond the scope of this review to com-
pare the incidence of cough under zofenopril with that 
observed with other ACE inhibitors, it must be recognized 
that the incidence of cough under zofenopril was relatively 
low (2.4%). This is probably related to its pharmacological 
features, in particular its potentially lower ability to induce 
local production of kinins and prostaglandins than other ACE 
inhibitors. This has been shown in some experimental and 
animal studies summarized and discussed in the following 
paragraphs.
According to ex vivo animal studies, normalized oral 
doses of zofenopril, captopril, enalapril, fosinopril, lisinopril, 
and ramipril have equivalent effects on serum ACE, but the 
strength and duration of ACE inhibition with zofenopril is 
not the same in different tissues, particularly in the lungs.18 
For instance, at the heart level, where ACE inhibition may 
prevent ischemic damage, zofenopril produces a more strik-
ing and long-lasting ACE inhibition than ramipril and enal-
april, and to a lesser extent than captopril and fosinopril. As 
a matter of fact, 8 hours after administration, ACE inhibitor 
activity in the heart is approximately 60% with zofenopril, 
close to 0% with ramipril and enalapril, and about 30% with 
captopril and fosinopril.18 After 24 hours, cardiac ACE is 
inhibited by approximately 45% with zofenopril, while the 
effects of equivalent oral doses of other ACE inhibitors have 
virtually disappeared by this time (1%–10%). As shown in 
an ex vivo study performed in rats, in the lung zofenopril 
is distinguished for its lower ACE inhibition potency in the 
long term compared to other ACE inhibitors (Figure 6) and 
to other districts (eg, 40% less potent in the lung than in the 
heart).18,94 Though direct evidence on the characteristics of 
bradykinin production is lacking, this finding might at least 
partially explain the relatively low risk of coughing observed 
with zofenopril.
Indeed, the power of zofenopril to stimulate the pro-
duction of prostaglandins, either directly or by inhibiting 
bradykinin metabolism, is lesser than other ACE inhibitors, 
as reported in animal studies. In anesthetized open-chest 
dogs, improvement of myocardial contractile function 
after left anterior descending coronary artery occlusion 
associated with enalapril treatment was largely reversed by 
indomethacin, known to inhibit myocardial prostaglandin 
synthesis (segment shortening reduced by 69% ± 12% 
at 2 hours after treatment/reperfusion to 38% ± 12% at 
2 hours after indomethacin; P , 0.01).95 However, the drug 
had no effect on the improved contractile function associ-
ated with zofenopril (segment shortening was enhanced by 
75% ± 10% at 2 hours after reperfusion and was maintained 
at 72% ± 8% 2 hours after indomethacin), indicating a dif-
ferent mechanism of action for the two drugs.95 Such an 
effect has also been recently demonstrated at the lung level. 
In one study, 2 weeks of oral treatment of guinea pigs with 
zofenopril (10 mg/kg/die) did not change the number of 
cough episodes following 0.1 M of citric acid aerosol as 
compared to control (15.0 ± 1.8 vs 16.0 ± 1.4), while this 
number was significantly (P , 0.05) increased after treatment 
with ramipril (21.0 ± 1.8 and 24.0 ± 2.5 at 3 mg/kg/die and 
10 mg/kg/die, respectively).96 In another experimental study Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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performed in rabbits, the animals were exposed to 1 M of 
nebulized citric acid for 3 minutes following 30 minutes of 
treatment with intravenous saline, zofenoprilat, or ramip-
rilat, the active metabolites of the prodrugs zofenopril and 
ramipril, at equieffective blood pressure reducing doses.97 
Both saline and zofenoprilat did not induce any significant 
difference in the number of cough episodes (13.1 ± 1.3 and 
15.8 ± 4.3 vs 15.2 ± 2.3 and 16.1 ± 4.9, respectively), while 
ramiprilat induced a significant increase in number of coughs 
(34.9 ± 3.5 vs 21.1 ± 2.6; P , 0.01). These two studies sup-
port the hypothesis of a difference in the protussive activity 
of zofenopril and ramipril, probably due to a difference in the 
activation of cyclooxygenase-2, which reflects on a different 
ability to induce accumulation of bradykinin and prostaglan-
din synthesis. Indeed, an indirect support to this hypothesis 
is given by a study in which ramipril was reported to induce 
increase in cyclooxygenase-2 expression in lungs of mice and 
in cultures of human endothelial cells.98 Ramipril-induced 
cough has also been associated with increased (by 36%) of 
bradykinin levels in the bronchoalveolar lavage fluid and with 
a marked increase (by 232%) in prostaglandin EM, a metabo-
lite of prostaglandin E2.96 In the same experimental condition, 
zofenopril was employed for comparison and the compound 
did not enhance bradykinin and prostaglandin EM as com-
pared to controls. Also, captopril was found to increase pros-
taglandin E2 production in hypertensive patients.99 This lower 
stimulation of kinin production by zofenopril might be 
explained by its lower ACE inhibition potency at lung level in 
the long term compared to captopril and moreover to ramipril 
(Figure 6). However, evidence is needed in direct compara-
tive studies in humans to fully support this hypothesis.
Conclusion
ACE inhibitors are widely administered to treat numerous 
medical conditions, but their use may be associated with 
a dry cough that can lead to treatment discontinuation. 
Though this adverse drug reaction has been observed with 
all ACE inhibitors, its incidence may vary among the vari-
ous agents.
According to analysis of individual data from several 
double-blind randomized and open-label studies, zofenopril 
seems to have a relatively low incidence of cough, which 
might be related to its limited ACE inhibitor potency at the 
lung level in the long term, responsible for a lesser accumula-
tion of bradykinin and a reduced synthesis of prostaglandins 
in this tissue, as found in animal studies.
Large head-to-head comparative clinical trials with other 
ACE inhibitors in humans are still needed to demonstrate 
whether the incidence of cough under zofenopril may or may 
not significantly differ in respect to other ACE inhibitors. 
Notwithstanding this consideration, some important clinical 
implications of the findings must be highlighted. First, the 
results provide further evidence to the existing evidence, 
namely that dry cough is not an uncommon phenomenon 
during treatment with all ACE inhibitors. Physicians should 
be aware of this relationship when treating their hypertensive 
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Figure 6 Changes (%) in the inhibition of lung angiotensin-converting enzyme activity as a function of time (hours and days) after administration of equivalent oral doses of 
zofenopril (full circles), captopril (open circles), enalapril (open squares), ramipril (open triangles), lisinopril (open stars), and fosinopril (open diamonds) in 42 rats (ex vivo study).
Notes: Asterisks refer to the statistical significance at each time point versus control for zofenopril (**P , 0.01; *P , 0.05). 
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and cardiac patients, and probably should pay more attention 
to patients’ medical histories to prevent or reduce the risk of 
occurrence of such an adverse event. Second, results of the 
analysis suggest that not all ACE inhibitors have the same 
chance of inducing dry cough, probably because of poten-
tially different pharmacological features. This aspect should 
be taken into account when a potential risk of dry cough exists 
and when treatment with an ACE inhibitor is unavoidable. 
Third, there is no proven effective treatment of ACE inhibitor-
induced cough. Physicians should understand that when a 
patient is experiencing ACE inhibitor-related cough, the only 
possibility to avoid this effect is to stop treatment.
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